Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments: 2015-2025

Historic Preferred Dividend Payments for Cartesian Therapeutics (RNAC) over the last 1 years, with Jun 2025 value amounting to -$2.6 million.

  • Cartesian Therapeutics' Preferred Dividend Payments rose 37.55% to -$2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.3 million, marking a year-over-year decrease of 183.03%. This contributed to the annual value of $4.6 million for FY2016, which is 37.75% down from last year.
  • According to the latest figures from Q2 2025, Cartesian Therapeutics' Preferred Dividend Payments is -$2.6 million, which was up 37.55% from -$4.2 million recorded in Q2 2024.
  • Cartesian Therapeutics' Preferred Dividend Payments' 5-year high stood at -$2.6 million during Q2 2025, with a 5-year trough of -$4.2 million in Q2 2024.
  • Its 2-year average for Preferred Dividend Payments is -$3.4 million, with a median of -$3.4 million in 2024.
  • Data for Cartesian Therapeutics' Preferred Dividend Payments shows a peak YoY spiked of 37.55% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Cartesian Therapeutics' Preferred Dividend Payments stood at -$4.2 million in 2024, then spiked by 37.55% to -$2.6 million in 2025.
  • Its Preferred Dividend Payments stands at -$2.6 million for Q2 2025, versus -$4.2 million for Q2 2024 and $2.2 million for Q2 2016.